Document is current
Any future updates will be listed below
-
Authors
Bergstra, S. A. https://orcid.org/0000-0002-7136-5248
van Ouwerkerk, L.
Nevins, I. S.
van der Pol, J. A.
Helmich, G. S.
Hest, I.
van Veen, A.
Bos, R.
Goekoop-Ruiterman, Y. P. M.
Vonkeman, H. E.
Bijsterbosch, J.
de Jong, P. H. P.
Güler-Yüksel, M.
Böhringer, S.
Huizinga, T. W. J.
van Gaalen, F. A.
- License Information
-
More Information
Article History
Received: 27 June 2024
Accepted: 4 November 2024
First Online: 13 November 2024
Declarations
:
: The study is carried out in compliance with the recommendations of the Declaration of Helsinki, GCP, and in accordance with local guidelines, regulations, and acts. The medical ethical committee of the Leiden University Medical Center (reference P20.027) and all other participating hospitals approved the trial. Patients give informed consent before they are randomized in the study.
: SAB has received funding from Pfizer (payments made to the LUMC) and speaker fees from Benecke.FvG has received consulting fees from, Abbvie, ASAS, BMS, Galapagos, Janssen, Lilly, Novartis, Pfizer, and UCB with all payments made to the LUMC.RB received research grants from Galapagos and Sanofi and consulting fees from Abbvie, Galapagos, Janssen, Pfizer, and UCB.JavdP, LvO, IS, PdJ, HV, SB, YGR: none.
